+44 20 7242 8692
Hugh has an extensive practice with clients ranging from large and long-established global companies (e.g. Janssen Biotech, Janssen Sciences, Shire, Gilead, Celgene, Regeneron and Vertex) through to European biotech companies (eg, Akari, Hubrecht Institute, Gene Bridges and Tigenix). During his career, he has been responsible for establishing the filing strategy and generating IP portfolios for a number of start-ups, guiding some of these clients all the way from early conception through financing rounds and subsequent public flotation. His particular area of current focus includes biologics – in particular, therapeutic antibodies, complex immunology, biosimilars and stem cells. Collectively, these experiences have developed Hugh’s ability to consistently and successfully protect foundation intellectual property and forecast potential future problems from the viewpoint of both IP generation and freedom to operate.
Hugh received his BA (Hons) in biochemistry and his MA and DPhil from Oxford University. His experience at the bench was spent investigating mechanisms of drug resistance in cancer cells.
Key IP Practice Areas
- Dispute Resolution
- Due Diligence/IP Audit
- Freedom to Operate
- Patent Prosecution and Appeals
- Supplementary Protection Certificates
- Validation of European Patents
- Pharmaceuticals, Biotechnology & Life Sciences
Last updated 26th January 2018